Eli Lilly and Company (NYSE:LLY) Shares Sold by First Horizon Advisors Inc.

First Horizon Advisors Inc. trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 3.2% during the 4th quarter, Holdings Channel reports. The institutional investor owned 12,663 shares of the company’s stock after selling 416 shares during the period. First Horizon Advisors Inc.’s holdings in Eli Lilly and Company were worth $7,382,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the business. Simon Quick Advisors LLC grew its stake in Eli Lilly and Company by 10.5% during the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after purchasing an additional 278 shares during the last quarter. Clear Harbor Asset Management LLC acquired a new position in Eli Lilly and Company in the 4th quarter worth approximately $363,000. Terril Brothers Inc. increased its holdings in Eli Lilly and Company by 113.2% in the 4th quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock worth $471,000 after buying an additional 429 shares during the period. Hartline Investment Corp raised its position in Eli Lilly and Company by 1.1% during the 4th quarter. Hartline Investment Corp now owns 21,934 shares of the company’s stock worth $12,786,000 after buying an additional 248 shares during the last quarter. Finally, Meritage Portfolio Management boosted its holdings in shares of Eli Lilly and Company by 23.4% in the 4th quarter. Meritage Portfolio Management now owns 6,377 shares of the company’s stock valued at $3,717,000 after acquiring an additional 1,208 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on LLY shares. Bank of America boosted their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Barclays lifted their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. JPMorgan Chase & Co. upped their price objective on Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research report on Wednesday. DZ Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a research note on Wednesday, February 21st. Finally, Morgan Stanley boosted their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research note on Friday, February 16th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $757.95.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded down $20.94 during midday trading on Friday, hitting $734.97. The company had a trading volume of 4,535,213 shares, compared to its average volume of 3,087,178. Eli Lilly and Company has a twelve month low of $419.80 and a twelve month high of $800.78. The stock has a market cap of $698.52 billion, a price-to-earnings ratio of 108.24, a price-to-earnings-growth ratio of 1.57 and a beta of 0.37. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 0.73. The business’s 50-day simple moving average is $761.75 and its 200-day simple moving average is $670.56.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The business had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company’s revenue for the quarter was up 26.0% on a year-over-year basis. During the same period last year, the company earned $1.62 EPS. On average, research analysts predict that Eli Lilly and Company will post 13.49 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.